Systematic review of high-dose and standard-dose chemotherapies in the treatment of primary well-differentiated osteosarcoma
Tumor Biology - 2014
Tóm tắt
The objective of this study is to evaluate whether high-dose chemotherapy is more efficacious than standard-dose chemotherapy in the treatment of primary well-differentiated osteosarcoma. The Cochrane systematic evaluation method was adopted. A database search was conducted in MEDLINE, Embase, OVID, the Cochrane Central Register of Controlled Trials database and the Chinese Biomedical Literature CD-ROM Database. The quality of the included studies was jointly evaluated by two reviewers, and homogeneous studies were included for meta-analysis. A total of five studies were included in this meta-analysis, with 1,415 subjects with primary, nonmetastatic, well-differentiated osteosarcoma in the limbs. No statistically significant differences were found between the high-dose chemotherapy group and the low-dose group in 5-year event-free survival [RR 1.04, 95 %CI (0.95, 1.13)], 5-year overall survival [RR 1.02, 95 %CI (0.95, 1.10)], local recurrence rate [RR 0.90, 95 %CI (0.59, 1.39)], proportion of subjects with good histological response [RR 0.93, 95 %CI (0.81, 1.07)], or limb salvage rate [RR 0.97, 95 %CI (0.92, 1.02)]. A statistically significant difference was observed in the 5-year event-free survival between the subjects with good histological response to preoperative chemotherapy and the subjects with poor histological response [RR 1.55, 95 %CI (1.19, 2.00), P < 0.001]. High-dose chemotherapy did not show superior efficacy to low-dose chemotherapy in the treatment of primary well-differentiated osteosarcoma. Further high-quality randomized controlled trials are needed to provide additional reliable evidence for our observation.
Từ khóa
Tài liệu tham khảo
Lopez-Beltran A, Montironi R, Carazo JL, Vidal A, Cheng L. Primary renal osteosarcoma. Am J Clin Pathol. 2014;141:747–52.
Blakey K, Feltbower RG, Parslow RC, James PW, Gómez Pozo B, Stiller C, et al. Is fluoride a risk factor for bone cancer? Small area analysis of osteosarcoma and Ewing sarcoma diagnosed among 0–49-year-olds in Great Britain, 1980–2005. Int J Epidemiol. 2014;43(1):224–34.
Choi LE, Healey JH, Kuk D, Brennan MF. Analysis of outcomes in extraskeletal osteosarcoma: a review of fifty-three cases. J Bone Joint Surg Am. 2014;96:e2.
Dahlin D, Coventry M. Osteogenic sarcoma: a study of six hundred cases. J Bone Joint Surg Am. 1975;57:397–404.
Enneking WF. An abbreviated history of orthopaedic oncology in North America. Clin Orthop Relat Res, 2000: 115–124.
Huang KL, Chen CF, Wu PK, Chen PC, Chen WM, Liu CL, et al. Clinical outcomes and prognostic factors of Ewing sarcoma: a clinical analysis of 12 patients in Taiwan. J Chin Med Assoc. 2012;75:16–20.
Campanacci M, Bacci G, Bertoni F, et al. The treatment of osteosarcoma of the extremities: twenty years’ experience at the Istituto Ortopedico Rizzoli. Cancer. 1981;48:1569–81.
Hudson M, Jaffe MR, Jaffe N, et al. Pediatric osteosarcoma: therapeutic strategies, results and alprognostic factors derived from a 10-year experience. J Clin Oncol. 1990;8:1988–97.
Jaffe N. Adjuvant chemotherapy in osteogenic sarcoma. J Clin Oncol. 1984;2(10):1179–81.
Meyers PA, Heller G, Healey J, et al. Chemotherapy for non-metastatic osteosarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol. 1992;10(1):5–15.
Eilber F, Giuliano A, Eckardt J, et al. Adjuvant chemotherapy for osteosarcoma: a randomised prospective trial. J Clin Oncol. 1987;5(1):21–6.
Whelan JS, Jinks RC, McTiernan A, Sydes MR, Hook JM, Trani L, et al. Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials. Ann Oncol. 2012;23:1607–16.
Gaetano B, Cristiana F, Stefano F, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome. J Pediatr Hematal Oncol. 2003;25:845–53.
Meyers PA, Gorlick R, Hellr G, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (t12) protocol. J Clin Oncol. 1998;16:2452–8.
Bacci G, Gherlinzoni F, Picci P, et al. Adriamycin-methotrexate high dose as versus adriamycin-methotrexate moderate dose as adjuvant chemotherapy for osteosarcoma of the extremities: a randomized study. Eur J Clin Oncol. 1986;22:1337–45.
Souhami L, Craft AW, Van der Eijken JW, et al. Randomized trial of two regimens of chemotherapy in operative osteosarcoma: a study of the European osteosarcoma intergroup. Lancet. 1997;350(9082):911–7.
Granowetter L, Womer R, Devidas M, Krailo M, Wang C, Bernstein M, et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children’s Oncology Group Study. J Clin Oncol. 2009;27:2536–41.
Meyers PA, Gorlick R. Osteosarcoma. Pediatr Clin North Am. 1997;44(3):973–89.
Rosen G, Marcove RC, Caparros B, et al. Primary osteogenic sarcoma: the rational for preoperative chemotherapy and delayed surgery. Cancer. 1979;43:2163–77.